Latest Articles

Publication Date
Levonorgestrel intrauterine system versus dienogest effect on quality of life of women with deep endometriosis: a randomized open-label clinical trial.

Women with deep infiltrating endometriosis (DIE) can benefit from the use of progestins. Our aim is to explore if levonorgestrel-releasing intrauterine system (LNG-IUS) non inferior to dienogest (DNG) in improving …

Published: Aug. 7, 2024, midnight
Mimics of primary ovarian cancer and primary peritoneal carcinomatosis - A pictorial review.

Numerous conditions can mimic ovarian malignancy. Identifying the origin of a pelvic mass or disseminated peritoneal abnormality on imaging is important to ensure that the patient receives optimal management by …

Published: July 9, 2024, midnight
The ignored structure in female fertility: cilia in the fallopian tubes.

Cilia in the fallopian tubes (CFT) play an important role in female infertility, but have not been explored comprehensively. This review reveals the detection techniques for CFT function and morphology, …

Published: July 4, 2024, midnight
Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer - OncLive

Dostarlimab/Chemotherapy Under EMA Review for Primary Advanced/Recurrent Endometrial Cancer OncLive

Published: June 24, 2024, 7 a.m.
FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma - Medical Xpress

FDA approves Keytruda plus chemo for primary advanced, recurrent endometrial carcinoma Medical Xpress

Published: June 24, 2024, 7 a.m.
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma - HealthDay

FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma HealthDay

Published: June 21, 2024, 7 a.m.
Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer - Frontiers

Cost-effectiveness of dostarlimab plus chemotherapy for primary advanced or recurrent endometrial cancer Frontiers

Published: June 20, 2024, 7 a.m.
FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer - Pharmaceutical Executive

FDA Approves AstraZeneca’s Imfinzi for Mismatch Repair Deficient Primary Advanced or Recurrent Endometrial Cancer Pharmaceutical Executive

Published: June 17, 2024, 7 a.m.
Effect of Oral Contraceptive Use in Relation to Fertile Years on the Risk of Endometriosis in Women with Primary Infertility: A Ten-Year Single-Centre Retrospective Analysis.

Background and Objectives: Oral contraceptives (OCs) are usually used to treat endometriosis; however, the evidence is inconsistent about whether OC use in the past, when given to asymptomatic women, is …

Published: June 10, 2024, midnight
Delayed metastatic endometrial carcinoma mimicking primary colon adenocarcinoma: A surprise histopathological finding - Wiley Online Library

Delayed metastatic endometrial carcinoma mimicking primary colon adenocarcinoma: A surprise histopathological finding Wiley Online Library

Published: May 27, 2024, 7 a.m.
Link copied to clipboard!
Subscribe to Our Newsletter

Stay updated with our latest articles!